NVO Novo Nordisk
What matters nowUpdated 4 days ago
- On 2 October the FDA extended its review of denecimig, Novo's haemophilia A treatment, with no new decision date; the agency attributes the delay to remediation at the manufacturing facility and found no deficiencies in clinical efficacy or safety, and Novo still targets a US launch in the first half of 2027 1. On 29 September Novo licensed Hengrui's once-weekly oral GLP-1/GIP candidate HRS-1596 for a $300 million upfront and up to $2.6 billion in milestone and sales-linked value, with closing expected in Q4 2026 subject to US antitrust clearance 2.
- On 21 September the shares fell as much as 9% intraday as analysts called the new targets underwhelming and questioned pricing power and deal strategy ahead of semaglutide patent expiries in the early 2030s 3; the move for that day was -6.43%, a statistically large move (z-score -3.62). The same day Novo reported that CagriSema beat tirzepatide 5 mg on weight loss at week 60 in REIMAGINE 5 and cut weight by 21.0% versus 2.0% for placebo at week 68 in REDEFINE 9 4.
- NVO trades at a pooled 24/7 venue price of 38.44, down 0.56% from the previous close of 38.65, with open interest of $3.9 million across 3 venues.
- Over the twelve months to 31 December 2025, revenue was 309.1 billion, up 6.4% year on year, with a gross margin of 81.0%, an operating margin of 41.3%, free cash flow of 59.0 billion and EPS of 23.03, up 1.8%; net debt stood at 215.9 billion. No insider buys or sells were recorded in the 180 days to the snapshot.
- Next, Novo reports nine-month 2026 results on 4 November 2026, and the FDA decision on CagriSema for weight management is expected in Q4 2026, following the new drug application filed in December 2025 4. The Wegovy 7.2 mg single-dose pen EU rollout is planned for the second half of 2026.
Novo Nordisk · Oct 2
Novo Nordisk · Sep 29
Reuters · Sep 21
Novo Nordisk · Sep 21
Valuation & fundamentalsFull financials →
TTM through 2025-12-31 from SEC filings↗. Ratios use our pooled 24/7 price. Statements are in DKK; ratios convert at the latest Fed/ECB reference rate. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| binance perp NVOUSDT · 1 min ago | 38.92 | +0.01% | $373.0K | $2.3M | 0.0000% |
| aster perp NVOUSDT · 1 min ago | 39.32 | +1.04% | $11.2K | $1.1K | 0.0000% |
| bybit perp NVOUSDT · stale | 39.00 | +0.22% | $83.9K | $1.0M | 0.0000% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
FDA extends review of denecimig haemophilia A BLA over manufacturing remediation
The FDA is still reviewing Novo's biologics license application for denecimig, a haemophilia A treatment, and has set no new decision date.
OCTANE real-world data: switchers to the Wegovy pill lose 4.1% in three months
Real-world OCTANE data on the Wegovy pill, presented at EASD 2026 on 30 September, showed adults who switched from injectable tirzepatide or semaglutide to the pill lost an average of 4.1% of body weight after three months on treatment.
Novo licenses Hengrui's once-weekly oral GLP-1/GIP candidate for $300 million upfront
Novo signed a license agreement with China's Hengrui Pharma for HRS-1596, a phase 1-ready GLP-1 and GIP receptor dual agonist that may be dosed once weekly by mouth.
Novo shares fall as much as 9% as investors question pricing power and deals
Novo shares fell as much as 9% intraday on 21 September 2026 and were down about 4.4% by midday in Copenhagen after recovering some losses.
CagriSema beats tirzepatide 5 mg on weight in REIMAGINE 5 and 21% weight loss in REDEFINE 9
Novo reported topline phase 3 results for CagriSema on 21 September 2026.
Novo to present 44 abstracts at EASD 2026 including Wegovy pill real-world data
Novo said it will present 44 abstracts at the EASD 2026 diabetes meeting in Milan from 28 September to 2 October, covering semaglutide, CagriSema and zenagamtide.
Novo buys back DKK 314 million of B shares in week to 4 September
Novo repurchased 1,055,000 B shares for about DKK 314 million in the week from 31 August to 4 September 2026, at average prices between about DKK 292 and DKK 305.
Wegovy pill goes on sale in Germany, the first EU market
Novo launched the Wegovy pill in Germany from 1 September 2026, making Germany the first EU country to sell the tablet.
Novo Nordisk Q2 2026 profit beats forecasts and raises full-year outlook
Novo reported Q2 2026 adjusted sales of DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit of DKK 33,389 million, up 11%.
Novo shares fall about 6% despite raised outlook on Wegovy pill sales miss
Novo's US-listed shares fell about 6% on 4 August, the day the company beat profit forecasts and raised its 2026 outlook.
CagriSema matches tirzepatide on weight but misses HbA1c non-inferiority
In the 68-week open-label REIMAGINE 4 trial in adults with type 2 diabetes, CagriSema 2.4/2.4 mg was non-inferior to tirzepatide 15 mg for weight reduction but not for HbA1c reduction.
ZEUS Phase 3 trial of ziltivekimab misses cardiovascular endpoint
Ziltivekimab 15 mg, given once monthly, did not reduce major adverse cardiovascular events versus placebo in the ZEUS Phase 3 trial of more than 6,300 people with cardiovascular disease, chronic kidney disease and elevated inflammation.
EU approves Wegovy pill as first oral GLP-1 for weight management
The European Commission granted marketing authorisation for the Wegovy pill, once-daily oral semaglutide 25 mg, for adults with obesity or with overweight plus at least one weight-related condition.
Wegovy pill launches in the UK and UAE as US prescriptions top 265,000 a week
The Wegovy pill launched in the UAE in June and in the UK in July 2026, with early uptake described as encouraging.
CagriSema diabetes trials REIMAGINE 1-3 show HbA1c and weight reductions at ADA 2026
Novo Nordisk presented REIMAGINE 1 to 3 data for CagriSema 2.4 mg/2.4 mg in type 2 diabetes at the ADA Scientific Sessions in New Orleans, June 5 to 8, 2026.